Zolmitriptan transdermal - Zosano Pharma

Drug Profile

Zolmitriptan transdermal - Zosano Pharma

Alternative Names: ADAM-Zolmitriptan; M 207; Triptan microneedle patch - Zosano Pharma; Triptan patch - Zosano Pharma; Triptan transdermal - Zosano Pharma; Zolmitriptan Intracutaneous Microneedle System; ZP triptan -Zosano Pharma; ZP-Zolmitriptan; ZP-Zolmitriptan Intracutaneous Microneedle System

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zosano Pharma
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 03 Apr 2018 Zosano Pharma announces intention to file NDA with the US FDA for Migraine in fourth quarter of 2019
  • 02 Mar 2018 Zosano Pharma has patent protection for M 207 in USA
  • 03 Jan 2018 Zosano Pharma receives patent allowance for zolmitriptan transdermal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top